Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response

NCT00319800 is registered in ClinicalTrials.gov with Gachon University Gil Medical Center as lead sponsor.

NCT NCT00319800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00319800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response
Lead sponsor
Gachon University Gil Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2006
Completion date
March 31, 2007
Enrollment
50
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer